<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240305193729&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240305193729&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 06 Mar 2024 00:37:30 +0000</lastbuilddate>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae112. doi: 10.1093/eurheartj/ehae112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442294</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae112>10.1093/eurheartj/ehae112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442294</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:creator>Christopher Paul Cannon</dc:creator>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders</dc:title>
<dc:identifier>pmid:38442294</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae112</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae110. doi: 10.1093/eurheartj/ehae110. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442292</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae110>10.1093/eurheartj/ehae110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442292</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:creator>Tommaso Gori</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in interventional cardiology</dc:title>
<dc:identifier>pmid:38442292</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae110</dc:identifier>
</item>
<item>
<title>Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae102. doi: 10.1093/eurheartj/ehae102. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442291</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae102>10.1093/eurheartj/ehae102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442291</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Naisam Abbas</dc:creator>
<dc:creator>Jonas A Haas</dc:creator>
<dc:creator>Ke Xiao</dc:creator>
<dc:creator>Maximilian Fuchs</dc:creator>
<dc:creator>Annette Just</dc:creator>
<dc:creator>Andreas Pich</dc:creator>
<dc:creator>Filippo Perbellini</dc:creator>
<dc:creator>Christopher Werlein</dc:creator>
<dc:creator>Fabio Ius</dc:creator>
<dc:creator>Arjang Ruhparwar</dc:creator>
<dc:creator>Jan Fiedler</dc:creator>
<dc:creator>Natalie Weber</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo</dc:title>
<dc:identifier>pmid:38442291</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae102</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae113. doi: 10.1093/eurheartj/ehae113. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442290</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae113>10.1093/eurheartj/ehae113</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442290</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Juan Carlos Kaski</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease</dc:title>
<dc:identifier>pmid:38442290</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae113</dc:identifier>
</item>
<item>
<title>Cardiac magnetic resonance in the assessment of the anomalous right coronary artery originating from the left sinus of Valsalva</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae129. doi: 10.1093/eurheartj/ehae129. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae129>10.1093/eurheartj/ehae129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442289</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Mauro Lo Rito</dc:creator>
<dc:creator>Silvia Pica</dc:creator>
<dc:creator>Monica De Gaspari</dc:creator>
<dc:creator>Ilaria Rigato</dc:creator>
<dc:creator>Martina Perazzolo Marra</dc:creator>
<dc:creator>Giorgio De Conti</dc:creator>
<dc:creator>Simone Corradin</dc:creator>
<dc:creator>Raffaella Motta</dc:creator>
<dc:creator>Valeria Pergola</dc:creator>
<dc:creator>Francesco Secchi</dc:creator>
<dc:creator>Massimo Lombardi</dc:creator>
<dc:creator>Barbara Bauce</dc:creator>
<dc:creator>Alessandro Zorzi</dc:creator>
<dc:creator>Gaetano Thiene</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Massimo Antonio Padalino</dc:creator>
<dc:creator>Domenico Corrado</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac magnetic resonance in the assessment of the anomalous right coronary artery originating from the left sinus of Valsalva</dc:title>
<dc:identifier>pmid:38442289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae129</dc:identifier>
</item>
<item>
<title>Frailty, genetic predisposition, and incident atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae130. doi: 10.1093/eurheartj/ehae130. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442287</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae130>10.1093/eurheartj/ehae130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442287</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Ying Sun</dc:creator>
<dc:creator>Yinuo Zhou</dc:creator>
<dc:creator>Bowei Yu</dc:creator>
<dc:creator>Kun Zhang</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Xiao Tan</dc:creator>
<dc:creator>Yingli Lu</dc:creator>
<dc:creator>Ningjian Wang</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty, genetic predisposition, and incident atrial fibrillation</dc:title>
<dc:identifier>pmid:38442287</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae130</dc:identifier>
</item>
<item>
<title>Benefits of coronary artery bypass grafting over percutaneous coronary intervention in left main disease: the strength of the evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae135. doi: 10.1093/eurheartj/ehae135. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442147</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae135>10.1093/eurheartj/ehae135</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442147</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Stefano Urso</dc:creator>
<dc:creator>Rafael Sadaba</dc:creator>
<dc:creator>Victor Dayan</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Benefits of coronary artery bypass grafting over percutaneous coronary intervention in left main disease: the strength of the evidence</dc:title>
<dc:identifier>pmid:38442147</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae135</dc:identifier>
</item>
<item>
<title>Leadless and scarless pacing: towards symbiotic nanogenerators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae124. doi: 10.1093/eurheartj/ehae124. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442144</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae124>10.1093/eurheartj/ehae124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442144</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Panos E Vardas</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leadless and scarless pacing: towards symbiotic nanogenerators</dc:title>
<dc:identifier>pmid:38442144</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae124</dc:identifier>
</item>
<item>
<title>Usefulness of endomyocardial biopsy using three-dimensional delivery system for the diagnosis of cardiac amyloidosis with complete atrioventricular block after transcatheter aortic valve implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae137. doi: 10.1093/eurheartj/ehae137. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442140</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae137>10.1093/eurheartj/ehae137</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442140</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Koji Sudo</dc:creator>
<dc:creator>Kazuto Nakamura</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Usefulness of endomyocardial biopsy using three-dimensional delivery system for the diagnosis of cardiac amyloidosis with complete atrioventricular block after transcatheter aortic valve implantation</dc:title>
<dc:identifier>pmid:38442140</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae137</dc:identifier>
</item>
<item>
<title>Peripartum cardiomyopathy: the challenge of predicting cardiac function recovery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442138/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae111. doi: 10.1093/eurheartj/ehae111. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442138</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae111>10.1093/eurheartj/ehae111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442138</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Carmen Basic</dc:creator>
<dc:creator>Maria Schaufelberger</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Peripartum cardiomyopathy: the challenge of predicting cardiac function recovery</dc:title>
<dc:identifier>pmid:38442138</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae111</dc:identifier>
</item>
<item>
<title>Treatments for pulmonary arterial hypertension: navigating through a network of choices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae106. doi: 10.1093/eurheartj/ehae106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38442135</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae106>10.1093/eurheartj/ehae106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442135</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Tyler Pitre</dc:creator>
<dc:creator>Jason Weatherald</dc:creator>
<dc:creator>Marc Humbert</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Treatments for pulmonary arterial hypertension: navigating through a network of choices</dc:title>
<dc:identifier>pmid:38442135</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae106</dc:identifier>
</item>
<item>
<title>Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38441940/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093/eurheartj/ehae105. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38441940/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38441940</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae105>10.1093/eurheartj/ehae105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38441940</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Nabil V Sayour</dc:creator>
<dc:creator>Ágnes M Paál</dc:creator>
<dc:creator>Pietro Ameri</dc:creator>
<dc:creator>Wouter C Meijers</dc:creator>
<dc:creator>Giorgio Minotti</dc:creator>
<dc:creator>Ioanna Andreadou</dc:creator>
<dc:creator>Antonella Lombardo</dc:creator>
<dc:creator>Massimiliano Camilli</dc:creator>
<dc:creator>Heinz Drexel</dc:creator>
<dc:creator>Erik Lerkevang Grove</dc:creator>
<dc:creator>Gheorghe Andrei Dan</dc:creator>
<dc:creator>Andreea Ivanescu</dc:creator>
<dc:creator>Anne Grete Semb</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Juan-Carlos Kaski</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Péter Ferdinandy</dc:creator>
<dc:creator>Zoltán V Varga</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence</dc:title>
<dc:identifier>pmid:38441940</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae105</dc:identifier>
</item>
<item>
<title>Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38441886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism of leaflet malcoaptation is related to the presence of a significant dilation of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093/eurheartj/ehae088. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism of leaflet malcoaptation is related to the presence of a significant dilation of the tricuspid annulus secondary to right atrial enlargement. In addition, there is an insufficient adaptive growth of tricuspid valve leaflets that become unable to cover the enlarged annular area. As opposed to the ventricular phenotype, in A-STR, the tricuspid valve leaflet tethering is typically trivial. The A-STR phenotype accounts for 10%-15% of clinically relevant tricuspid regurgitation and has better outcomes compared with the more prevalent ventricular phenotype. Recent data suggest that patients with A-STR may benefit from more aggressive rhythm control and timely valve interventions. However, little is mentioned in current guidelines on how to identify, evaluate, and manage these patients due to the lack of consistent evidence and variable definitions of this entity in recent investigations. This interdisciplinary expert opinion document focusing on A-STR is intended to help physicians understand this complex and rapidly evolving topic by reviewing its distinct pathophysiology, diagnosis, and multi-modality imaging characteristics. It first defines A-STR by proposing specific quantitative criteria for defining the atrial phenotype and for discriminating it from the ventricular phenotype, in order to facilitate standardization and consistency in research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38441886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38441886</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae088>10.1093/eurheartj/ehae088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38441886</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Denisa Muraru</dc:creator>
<dc:creator>Luigi P Badano</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Roberto M Lang</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Nina C Wunderlich</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Alison Duncan</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Tom De Potter</dc:creator>
<dc:creator>José L Zamorano Gómez</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Marta Sitges</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment</dc:title>
<dc:identifier>pmid:38441886</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae088</dc:identifier>
</item>
<item>
<title>Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38440901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Using spatial proteomics, we unraveled the heterogeneity of vascular cells in control individuals and patients with SSc. We identified CD34^(+);αSMA^(+);CD31^(+) VECs as a novel endothelial cell population that is increased in patients with SSc, expresses markers for endothelial-to-mesenchymal transition, and is located in close proximity to immune cells and myofibroblasts. CD34^(+);αSMA^(+);CD31^(+) VEC counts were associated with clinical outcomes of progressive fibrotic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 5. doi: 10.1161/CIRCRESAHA.123.323299. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Systemic sclerosis (SSc) is a connective tissue disease that can serve as a model to study vascular changes in response to inflammation, autoimmunity, and fibrotic remodeling. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular pathophysiology remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: We applied spatial proteomic approaches to deconvolute the heterogeneity of vascular cells at the single-cell level in situ and characterize cellular alterations of the vascular niches of patients with SSc.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Skin biopsies of patients with SSc and control individuals were analyzed by imaging mass cytometry, yielding a total of 90 755 cells including 2987 endothelial cells and 4096 immune cells. We identified 7 different subpopulations of blood vascular endothelial cells (VECs), 2 subpopulations of lymphatic endothelial cells, and 3 subpopulations of pericytes. A novel population of CD34<sup>+</sup>;αSMA<sup>+</sup> (α-smooth muscle actin);CD31<sup>+</sup> VECs was more common in SSc, whereas endothelial precursor cells were decreased. Co-detection by indexing and tyramide signal amplification confirmed these findings. The microenvironment of CD34<sup>+</sup>;αSMA<sup>+</sup>;CD31<sup>+</sup> VECs was enriched for immune cells and myofibroblasts, and CD34<sup>+</sup>;αSMA<sup>+</sup>;CD31<sup>+</sup> VECs expressed markers of endothelial-to-mesenchymal transition. The density of CD34<sup>+</sup>;αSMA<sup>+</sup>;CD31<sup>+</sup> VECs was associated with clinical progression of fibrosis in SSc.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using spatial proteomics, we unraveled the heterogeneity of vascular cells in control individuals and patients with SSc. We identified CD34<sup>+</sup>;αSMA<sup>+</sup>;CD31<sup>+</sup> VECs as a novel endothelial cell population that is increased in patients with SSc, expresses markers for endothelial-to-mesenchymal transition, and is located in close proximity to immune cells and myofibroblasts. CD34<sup>+</sup>;αSMA<sup>+</sup>;CD31<sup>+</sup> VEC counts were associated with clinical outcomes of progressive fibrotic remodeling, thus providing a novel cellular correlate for the crosstalk of vasculopathy and fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38440901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38440901</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323299>10.1161/CIRCRESAHA.123.323299</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38440901</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Aleix Rius Rigau</dc:creator>
<dc:creator>Yi-Nan Li</dc:creator>
<dc:creator>Alexandru-Emil Matei</dc:creator>
<dc:creator>Andrea-Hermina Györfi</dc:creator>
<dc:creator>Peter-Martin Bruch</dc:creator>
<dc:creator>Sarah Koziel</dc:creator>
<dc:creator>Veda Devakumar</dc:creator>
<dc:creator>Armando Gabrielli</dc:creator>
<dc:creator>Alexander Kreuter</dc:creator>
<dc:creator>Jiucun Wang</dc:creator>
<dc:creator>Sascha Dietrich</dc:creator>
<dc:creator>Georg Schett</dc:creator>
<dc:creator>Jörg H W Distler</dc:creator>
<dc:creator>Minrui Liang</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics</dc:title>
<dc:identifier>pmid:38440901</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323299</dc:identifier>
</item>
<item>
<title>Metabolic product of excess niacin is linked to increased risk of cardiovascular events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38438588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 4. doi: 10.1038/s41569-024-01005-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38438588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38438588</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01005-1>10.1038/s41569-024-01005-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38438588</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Metabolic product of excess niacin is linked to increased risk of cardiovascular events</dc:title>
<dc:identifier>pmid:38438588</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01005-1</dc:identifier>
</item>
<item>
<title>Shortening in-hospital stay after transcatheter aortic valve implantation: a déjà vu in percutaneous interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 4:ehae096. doi: 10.1093/eurheartj/ehae096. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437639</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae096>10.1093/eurheartj/ehae096</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437639</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Julinda Mehilli</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Shortening in-hospital stay after transcatheter aortic valve implantation: a déjà vu in percutaneous interventions</dc:title>
<dc:identifier>pmid:38437639</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae096</dc:identifier>
</item>
<item>
<title>Weekly journal scan: a new small-interfering RNA to fight a genetic cardiovascular risk factor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 4:ehae118. doi: 10.1093/eurheartj/ehae118. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437638</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae118>10.1093/eurheartj/ehae118</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437638</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: a new small-interfering RNA to fight a genetic cardiovascular risk factor</dc:title>
<dc:identifier>pmid:38437638</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae118</dc:identifier>
</item>
<item>
<title>Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The intervention was simple and fast to implement, and was effective and safe to reduce LOS and increase the proportion of patients discharged early after TAVI (NCT04503655).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 4:ehae081. doi: 10.1093/eurheartj/ehae081. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The length of stay (LOS) after transcatheter aortic valve implantation (TAVI) remains extremely variable whereas early discharge has been shown to be feasible and safe. The study objective was to evaluate the efficacy and safety of an intervention aimed at reducing LOS after transfemoral TAVI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAST-TAVI II is a prospective, multicentre, cluster, randomized, controlled study including patients with severe symptomatic aortic stenosis, who had transfemoral TAVI. The intervention consisted in a dedicated training programme to implement 10 quality of care measures to reduce LOS with an implementation phase of eight weeks. The primary endpoint was the proportion of patients discharged early within 3 days. Secondary endpoints included: LOS, 30-day mortality and 30-day incidence of readmission for cardiovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the study period, 969 patients were enrolled in the intervention group and 860 patients in the control group. Mean age was 81.9 ± 6.6 years and mean EuroSCORE II was 4.4 ± 4.5%. Early discharge was achieved in 563 (58.1%) patients in the intervention group vs. 364 (42.3%) patients in the control group (P &lt; .0001). Median LOS was significantly reduced in the intervention group compared to the control group [3 (IQR: 3) vs. 4 days (IQR: 3), P &lt; .0001]. Thirty-day mortality was low and similar in the two groups (0.5% vs. 0.9%, P = .30), as were 30-day readmissions (4.6% vs. 2.8%, P = .28).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The intervention was simple and fast to implement, and was effective and safe to reduce LOS and increase the proportion of patients discharged early after TAVI (NCT04503655).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437633</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae081>10.1093/eurheartj/ehae081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437633</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Eric Durand</dc:creator>
<dc:creator>Delphine Beziau-Gasnier</dc:creator>
<dc:creator>Morgane Michel</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Guillaume Bonnet</dc:creator>
<dc:creator>Thibault Lhermusier</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Geraud Souteyrand</dc:creator>
<dc:creator>Claire Bouleti</dc:creator>
<dc:creator>Patrick Ohlmann</dc:creator>
<dc:creator>Thierry Lefevre</dc:creator>
<dc:creator>Farzin Beygui</dc:creator>
<dc:creator>Stephan Chassaing</dc:creator>
<dc:creator>Karine Chevreul</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:creator>FAST-TAVI II</dc:creator>
<dc:creator>STOP-AS investigators</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial</dc:title>
<dc:identifier>pmid:38437633</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae081</dc:identifier>
</item>
<item>
<title>Weekly journal scan: do biodegradable polymer stents provide a durable benefit in patients with ST-segment elevation myocardial infarction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 4:ehae119. doi: 10.1093/eurheartj/ehae119. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437630</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae119>10.1093/eurheartj/ehae119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437630</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: do biodegradable polymer stents provide a durable benefit in patients with ST-segment elevation myocardial infarction?</dc:title>
<dc:identifier>pmid:38437630</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae119</dc:identifier>
</item>
<item>
<title>Thrombosis of a mechanical aortic valve: stuck between a clot and a hard place</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 4:ehae115. doi: 10.1093/eurheartj/ehae115. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437581</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae115>10.1093/eurheartj/ehae115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437581</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael McGregor</dc:creator>
<dc:creator>Hilary Bews</dc:creator>
<dc:creator>Davinder S Jassal</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thrombosis of a mechanical aortic valve: stuck between a clot and a hard place</dc:title>
<dc:identifier>pmid:38437581</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae115</dc:identifier>
</item>
<item>
<title>The Shape of Things to Come? Is a Trial of Combined Interventional Procedures Necessary in Today's World?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38437486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240305193729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 5;149(10):744-746. doi: 10.1161/CIRCULATIONAHA.123.067744. Epub 2024 Mar 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38437486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240305193729&v=2.18.0.post9+e462414">38437486</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067744>10.1161/CIRCULATIONAHA.123.067744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38437486</guid>
<pubDate>Mon, 04 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Neal S Kleiman</dc:creator>
<dc:creator>Sachin S Goel</dc:creator>
<dc:date>2024-03-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Shape of Things to Come? Is a Trial of Combined Interventional Procedures Necessary in Today's World?</dc:title>
<dc:identifier>pmid:38437486</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067744</dc:identifier>
</item>





























</channel>
</rss>